Responsibilities The REGISTRY Steering Committee will ensure that trial policies
governing confidentiality, human subjects, clinical practice,
conflict-of-interest and publication are consistent with policies contained in
the EHDN constitution.
The EHDN REGISTRY Steering Committee is responsible for
- selecting site investigators for the study. Participating site investigators for a trial should be selected from the current EHDN listing of qualified investigators who request participation in EHDN trials
- removing from active trial participation any steering committee members, investigators or other study personal who does not fulfill his/her obligations to the trial or who does not maintain the standards of EHDN with respect to confidentiality, professional conduct, rights of research subjects, conflict-of-interest, disclosure or publication policies.
- fostering recruitment into REGISTRY
- developing the protocol of REGISTRY further
- assisting the PI and Co-PI in the implementation and proper conduct of the trial
- collaborating with the Scientific Review Committee (SRC) of EHDN on approved EHDN projects using data and materials generated through REGISTRY
- Members of the steering committee – as all members of EHDN – are entitled to hand in proposals
GeneralThe task at hand calls for - clinicians of same standing in the position to foster recruitment
into REGISTRY i.e. senior physicians, well respected in their respective
region of origin
- geneticists to develop the family history component of REGISTRY and
to inspire genetic studies on the DNA collected
- scientist or clinician/scientist to develop the biomarker component
Structure- Principal investigator (PI) and Co-PI
- Members according to the criteria as defined above
- CHDI Foundation (Inc.) representative
AppointedServing as long as REGISTRY is an
active trial unless member resigns | | Members - A. C. Bachoud-Levi (France)
- A. R. Bentivoglio (Italy)
- R. Bonelli (Austria)
- J. M. Burgunder (Switzerland)
- J. Ferreira (Portugal)
- J. Frich (Norway)
- S. N. Illarioshkin (Russia)
- J. Klempír (Czech Republic)
- G. B. Landwehrmeyer (PI, Germany)
- J. Nielsen (Denmark)
- M. Päivärinta (Finland)
- S. Pålhagen (Sweden)
- M. Ramos (Spain)
- R.A.C. Roos (Netherlands)
- O. Quarrell (U.K.)
- C. Saft (Germyny)
- W. Vandenberghe, C. Verellen-Dumoulin (Belgium)
- J. Zaremba (Poland)
- O. Handley (PM REGISTRY, UK)
- J. Giuliano (Representative of the CHDI Foundation Inc.)
- I. Biunno (Biobank, Italy)
- S. Dunnett (Ethics, U.K.)
- T. Illmann (IT, Germany)
- S. Pro Kovisto (Registry Associated PM, Norway)
- S. Minister (Representative of language area coordinators)
- T. McLean (Clinical Operation Manager)
Ex Officio of the Executive Committee- J. Levey (COO)
- J. Bronzova
|